Connect your AI

BioLife Solutions BLFS Total Equity

Total Equity at other companies

Thermo Fisher ScientificTMO

$51.93B+5.2%

DanaherDHR

$52.95B+4.1%

AzentaAZTA

$1.55B-8.3%

LeMaitre VascularLMAT

$406.62M+17.0%

CryoPort, Inc.CYRX

$494.99M+24.1%

TEC

Bio-TechneTECH

——

Other financials

Income statement

Revenue$27.5M+24.7%

Gross profit$17.5M+18.2%

Operating income$27.0K+105%

Net income$1.2M+365%

EPS (diluted)$0.02—

Balance sheet

Cash & equivalents$22.8M-65.9%

Total debt$17.4M-35.6%

Total assets$400.9M+1.5%

Cash flow

Operating cash flow-$491.0K-128%

CapEx$167.0K-4.6%

Free cash flow-$658.0K-142%

Valuation

Market cap$1.25B+23.8%

Enterprise value$1.24B+28.3%

P/S12.5×-0.4×

Profitability

Gross margin66.9%—

Operating margin-16.7%—

Net margin-68.7%—

FCF margin-15.9%+18.7pp

Returns & leverage

Return on equity-14.5%-4.7pp

Debt / equity0×0.0×

Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioLife Solutions's total equity?: BioLife Solutions (BLFS) reported total equity of $372.23M in Q1 2026.
How has BioLife Solutions's total equity changed year-over-year?: BioLife Solutions's total equity increased by 5.6% year-over-year, from $352.62M to $372.23M.
What is the long-term trend for BioLife Solutions's total equity?: Over 5 years (2020 to 2025), BioLife Solutions's total equity has grown at a 12.7% compound annual growth rate (CAGR), from $204.43M to $371.89M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.